[A18-88] Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Last updated 01.04.2019

Project no.:

Commission awarded on 19.12.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


First-line treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are inelegible for cisplatin-containing first-line treatment and whose tumours have a PD-L1 expression ≥ 5%

Result of dossier assessment:

Added benefit not proven due to lack of suitable study data


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2019-06-20 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form